Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026Business Wire • 02/17/26
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy OutcomesBusiness Wire • 02/06/26
Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD TestZacks Investment Research • 02/03/26
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart TransplantationBusiness Wire • 01/28/26
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant CareBusiness Wire • 01/26/26
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal CancerBusiness Wire • 01/21/26
Natera's Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) MeetingBusiness Wire • 01/20/26
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI ModelingBusiness Wire • 01/13/26
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ GrowthBusiness Wire • 01/12/26
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal CancerBusiness Wire • 01/07/26
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ TechnologyBusiness Wire • 01/05/26